This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Song, L.-N. Articles by Gelmann, E. P. Search for Related Content PubMed PubMed Citation Articles by Song, L.-N. Articles by Gelmann, E. P.

Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C. 20057

Address all correspondence and requests for reprints to: Edward P. Gelmann, Department of Oncology, Lombardi Cancer Center, Georgetown University, 3800 Reservoir Road, Northwest, Washington, D.C. 20057. E-mail: gelmanne{at}georgetown.edu.

Mifepristone is a potent antagonist of steroid hormone receptors such as glucocorticoid and progesterone receptors. We investigated the potential for mifepristone to act as an antiandrogen and compared it with partial androgen receptor (AR) agonists and antagonists, in particular bicalutamide. Mifepristone was an effective antiandrogen in vitro that inhibited transcription from three androgen-responsive promoters and blocked the agonist R1881 in a dose-dependent manner. Like bicalutamide, mifepristone also antagonized the action of androgen receptor with a (T877A) mutation. Mifepristone competed effectively with R1881 with a relative binding affinity comparable to that of cyproterone acetate, and much higher than that of hydroxyflutamide and bicalutamide in a binding assay. Mifepristone could effectively induce the binding of the herpes simplex viral protein 16/AR fusion protein to the hormone response elements in the murine mammary tumor virus-luciferase reporter. With either wild-type or T877A mutant AR, mifepristone alone was unable to induce any detectable interaction with coactivators transcriptional intermediary factor-2 or ß-catenin but could inhibit the R1881-induced binding of AR to transcriptional intermediary factor-2 and ß-catenin. Similarly, mifepristone could inhibit the R1881-induced N/C-terminal interaction in a dose-dependent manner even though mifepristone alone has no effect on the N/C-terminal interaction of AR. We found that mifepristone could induce a strong interaction between AR and corepressors nuclear receptor corepressor and silencing mediator for retinoid and thyroid hormone receptors in both transactivation and two-hybrid assays to a greater degree than hydroxyflutamide, cyproterone acetate, and bicalutamide. The AR-corepressor interaction was also seen in coimmunoprecipitation assays. Finally, mifepristone at high concentrations induced a low level of prostate-specific antigen expression in LNCaP and antagonized prostate-specific antigen expression induced by R1881. Mifepristone also antagonized R1881 action on the growth of LNCaP prostate cancer cells.

NURSA Molecule Pages Link:

Nuclear Receptors:   AR

Coregulators:   GRIP1  |  NCOR  |  SMRT

Ligands:   17β-Estradiol  |  RU486  |  Bicalutamide  |  R1881

This article has been cited by other articles:

				M. C. Hodgson, H. C. Shen, A. N. Hollenberg, and S. P. Balk Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor Mol. Cancer Ther., October 1, 2008; 7(10): 3187 - 3194. [Abstract] [Full Text] [PDF]

				L.-N. Song and E. P. Gelmann Silencing Mediator for Retinoid and Thyroid Hormone Receptor and Nuclear Receptor Corepressor Attenuate Transcriptional Activation by the {beta}-Catenin-TCF4 Complex J. Biol. Chem., September 19, 2008; 283(38): 25988 - 25999. [Abstract] [Full Text] [PDF]

				A. Yemelyanov, J. Czwornog, L. Gera, S. Joshi, R. T. Chatterton Jr., and I. Budunova Novel Steroid Receptor Phyto-Modulator Compound A Inhibits Growth and Survival of Prostate Cancer Cells Cancer Res., June 15, 2008; 68(12): 4763 - 4773. [Abstract] [Full Text] [PDF]

				M. Agler, M. Prack, Yingjie Zhu, J. Kolb, K. Nowak, R. Ryseck, Ding Shen, M. E. Cvijic, J. Somerville, S. Nadler, et al. A High-Content Glucocorticoid Receptor Translocation Assay for Compound Mechanism-of-Action Evaluation J Biomol Screen, December 1, 2007; 12(8): 1029 - 1041. [Abstract] [PDF]

				H. V. Heemers, T. J. Sebo, J. D. Debes, K. M. Regan, K. A. Raclaw, L. M. Murphy, A. Hobisch, Z. Culig, and D. J. Tindall Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells Cancer Res., April 1, 2007; 67(7): 3422 - 3430. [Abstract] [Full Text] [PDF]

				T. I. Klokk, P. Kurys, C. Elbi, A. K. Nagaich, A. Hendarwanto, T. Slagsvold, C.-Y. Chang, G. L. Hager, and F. Saatcioglu Ligand-Specific Dynamics of the Androgen Receptor at Its Response Element in Living Cells Mol. Cell. Biol., March 1, 2007; 27(5): 1823 - 1843. [Abstract] [Full Text] [PDF]

				C. J Burd, L. M Morey, and K. E Knudsen Androgen receptor corepressors and prostate cancer Endocr. Relat. Cancer, December 1, 2006; 13(4): 979 - 994. [Abstract] [Full Text] [PDF]

				D. Kazmin, T. Prytkova, C. E. Cook, R. Wolfinger, T.-M. Chu, D. Beratan, J. D. Norris, C.-y. Chang, and D. P. McDonnell Linking Ligand-Induced Alterations in Androgen Receptor Structure to Differential Gene Expression: A First Step in the Rational Design of Selective Androgen Receptor Modulators Mol. Endocrinol., June 1, 2006; 20(6): 1201 - 1217. [Abstract] [Full Text] [PDF]

				H.-G. Yoon and J. Wong The Corepressors Silencing Mediator of Retinoid and Thyroid Hormone Receptor and Nuclear Receptor Corepressor Are Involved in Agonist- and Antagonist-Regulated Transcription by Androgen Receptor Mol. Endocrinol., May 1, 2006; 20(5): 1048 - 1060. [Abstract] [Full Text] [PDF]

				M. Wahab, A.H. Taylor, J.H. Pringle, J. Thompson, and F. Al-Azzawi Trimegestone differentially modulates the expression of matrix metalloproteinases in the endometrial stromal cell Mol. Hum. Reprod., March 1, 2006; 12(3): 157 - 167. [Abstract] [Full Text] [PDF]

				R. Obligacion, M. Murray, and I. Ramzan Drug-Metabolizing Enzymes and Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition J Androl, March 1, 2006; 27(2): 138 - 150. [Full Text] [PDF]

				M. C. Hodgson, I. Astapova, S. Cheng, L. J. Lee, M. C. Verhoeven, E. Choi, S. P. Balk, and A. N. Hollenberg The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists J. Biol. Chem., February 25, 2005; 280(8): 6511 - 6519. [Abstract] [Full Text] [PDF]

				Z. Kang, O. A. Janne, and J. J. Palvimo Coregulator Recruitment and Histone Modifications in Transcriptional Regulation by the Androgen Receptor Mol. Endocrinol., November 1, 2004; 18(11): 2633 - 2648. [Abstract] [Full Text] [PDF]

				D. Masiello, S.-Y. Chen, Y. Xu, M. C. Verhoeven, E. Choi, A. N. Hollenberg, and S. P. Balk Recruitment of {beta}-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells Mol. Endocrinol., October 1, 2004; 18(10): 2388 - 2401. [Abstract] [Full Text] [PDF]